ERBB2 and breast carcinoma: As there is considerable preclinical and clinical evidence that both EGFR and ErbB2 play a central role in driving acquisition of antihormone resistance in breast cancer [12-19], it is possible that antihormones may actually play an active role in limiting their own activity through an ability to promote expression of these potent growth promoters.